FARMINGDALE, N.Y., July 7, 2015 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, neurosurgery, wound debridement, laparoscopic surgery and other surgical applications, announced its attendance at the 22nd International Meeting on Advanced Spine Techniques ("IMAST") in Kuala Lumpur, Malaysia, from July 8-11, 2015. Misonix will be exhibiting and hosting a hands-on ultrasonic surgery workshop at IMAST this year.
The IMAST meeting is a three-day international forum with leading spine surgeons discussing, debating and demonstrating innovative surgical technologies that help improve patient care. The course includes the latest research on new and advanced techniques in treating scoliosis, trauma, tumors and degenerative diseases. The meeting is organized by the Scoliosis Research Society ("SRS"). The SRS membership includes more than 1,000 of the world's leading spine surgeons, researchers, physician assistants, etc., who are involved in the research and treatment of spinal pathologies. Last year's international meeting was attended by 776 delegates.
Misonix will showcase its ultrasonic BoneScalpel, which is rapidly gaining adoption by leading spine surgeons around the globe. The BoneScalpel provides unique benefits over traditional bone cutting tools as it offers clean, controlled bone incision and removal, while sparing elastic soft tissue structures such as the dura, nerves and arteries. The BoneScalpel has been reported to provide greater safety, reduced blood loss and blood transfusions, cell saver use, and decreased operative time in a variety of spine surgery procedures.
Dr. Peter Newton from Rady Children's Hospital in San Diego, CA will moderate the hands-on workshop, which will review clinical experiences and surgical benefits of the BoneScalpel over traditional technologies. The workshop will demonstrate these benefits along with surgical techniques and tips in a variety of spinal procedures, including deformity correction and minimally-invasive fusions. The presenting faculty includes Dr. Newton, Dr. Juan Uribe from the University of South Florida, Tampa, FL and Dr. Greg Mundis from Scripps Memorial Hospital, La Jolla, CA. Surgeon attendees will have the opportunity to trial the BoneScalpel on bone models and engage in detailed discussions with the faculty.
Dr. Peter Newton elaborated on his personal experience, "In my surgical experience, the BoneScalpel is safer than traditional methods for cutting bone in spine procedures. It also has allowed me to perform surgeries very efficiently with reduced blood loss and time savings." Dr. Mundis, of the presenting faculty, agreed, "The BoneScalpel offers greater clinical and economic efficiencies in my surgical practice."
Michael A. McManus, Jr., President and Chief Executive Officer of Misonix, commented, "We are enthusiastic about BoneScalpel's unique benefits and increasing utilization in advanced spine surgeries. IMAST is a renowned spine meeting and an important podium to showcase the BoneScalpel. We are also very excited to have another opportunity to host a BoneScalpel hands-on workshop presented by a talented team of surgical experts. We thank this distinguished group of surgeons for their participation and support. Last year's IMAST workshop created significant interest in the BoneScalpel, and we have no doubt this year will be even more successful."
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
SOURCE Misonix, Inc.